Abstract: The present application relates to process for preparation of Mavacamten, preparative methods of various crystalline forms of Mavacamten and amorphous form of Mavacamten, its preparative method, and pharmaceutical compositions thereof. The present application also relates to solid dispersions of Mavacamten, their preparative methods and pharmaceutical compositions containing solid dispersions of Mavacamten.

Abstract: Methods of making a multilayered semiconductor particle, which may be referred to as a quantum dot, are described. The methods include combining a first zinc-containing compound and a selenium-containing compound to form a ZnSe mixture. The zinc-containing compound and the selenium-containing compound are rapidly combined in less than or about 5 seconds. The methods also include adding a tellurium-containing compound to the ZnSe mixture to form at least one ZnSeTe particle in a ZnSeTe mixture. The methods still further include forming a first shell layer on the ZnSeTe particle and forming a second shell layer on the first shell layer to make the multilayered semiconductor particle. In additional embodiments, the reactant and particle mixtures may be rapidly stirred. The light emitted by the multilayered semiconductor particles may be characterized by an enhanced narrowband emission profile (i.e., sharpness).

Abstract: Aspects of the present application relate to process for the preparation of Omecamtiv mecarbil and salts thereof. Specific aspects relate to novel urea intermediate, preparative process thereof and its use in the preparation of Omecamtiv mecarbil and salts thereof. The improved process for the preparation of Omecamtiv mecarbil are industrially viable.

Abstract: Aspects of the present application relate to solid forms of Omecamtiv mecarbil dihydrochloride. Specific aspects relate to crystalline forms and amorphous solid dispersions of Omecamtiv mecarbil dihydrochloride. Further specific aspects related to crystalline forms DP1, DP2, DP3, DP4, OMT-D, OMT-L, OMT-O, OMT-F, OMT-FS and amorphous solid dispersions of Omecamtiv mecarbil dihydrochloride and pharmaceutical compositions thereof.

Abstract: The present application relates to crystalline forms R1-R10 of relugolix and process for preparation thereof. The present application also relates to amorphous form and amorphous solid dispersion of relugolix and process for preparation thereof. Crystalline forms R1 are stable under all storage conditions for three months. Crystalline form R1 have excellent physico-chemical properties and may be used conveniently in a pharmaceutical composition comprising relugolix. The application also relates to a process for purification of relugolix.

Abstract: Aspects of the present application relate to solid forms of Encequidar, its mesylate salt and pharmaceutical compositions thereof. Specific aspects relate to the crystalline Form E1 of Encequidar, crystalline Form EM1, crystalline Form EM2 and crystalline Form EM3 of Encequidar mesylate. Further aspects relate to processes for the preparation of solid forms of Encequidar and its mesylate salt.

Abstract: Aspects of the present application relate to process for the preparation of Pyrrolidine derivatives useful as key intermediates for active ingredients. Specific aspects relate to alternate process for the preparation of Upadacitinib intermediate, 4-ethylpyrrolidine-3-carboxylic acid, its ester or a salt thereof. Processes disclosed here in are cost effective and industrially viable as compared to known processes.

Abstract: Examples for detecting and removing non-natural language within natural language to enhance performing content analysis on the natural language are provided herein. A plurality of terms is identified in a phrase, and a sliding window having a defined length is placed over a first sequence of terms from the plurality of terms. The first sequence of terms includes a first term, a second term, and a third term, the first term and the third term being adjacent to the second term. Based on the first term, the second term, and the third term, a determination is made as to whether the second term represents non-natural language. Upon determining that the second term is non-natural language, the second term is labeled as non-natural language and is removed from the plurality of terms based on determining the second term as non-natural language.

Abstract: Active Content Wizards (ACWS) related to helping computer users perform tasks are executed using an ACW interpreter. In one aspect of the present invention, the interpreter provides multiple levels of user interaction for a given ACW script. In order to help focus the user's attention, various methods are used to increase the conspicuity of the user interface elements relative to sub-tasks during execution of the ACW script. In one embodiment, areas around the user interface element are also de-emphasized.

Abstract: A text generator automatically generating a text document based on the actions of an author on a user interface. To generate the text document the author activates a recording component. The recording component records the author's actions on the user interface. Based on the recorded actions, a text generation component searches a text database and identifies an entry that matches the author's recorded actions. This text is then combined to form a text document, which provides instruction or other information to a user. During the process of generating the text document, the text can be edited using an editor as desired, such as to enhance the comprehensibility of the document.